It has been shown that using tyrosine kinase inhibitor (TKIs) to inhibit PI3K/Akt signaling in NSCLC cell lines can lead to a decrease in cell membrane-localized GLUT1, but increases in TXNIP expression in lung cancer tissues (98). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.